Does Sensitive Cyp3a Substrates Interact with Adagrasib?
Sensitive Cyp3a Substrates and Adagrasib have a major drug interaction according to U.S. FDA drug labeling data. Adagrasib increases exposure of CYP3A4 substrates, which may increase the risk of adverse reactions related to these substrates. The mechanism involves cyp3a4 inhibition by adagrasib. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.
- Severity
- Major
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
How This Interaction Works
The interaction between Sensitive Cyp3a Substrates and Adagrasib occurs because cyp3a4 inhibition by adagrasib. Clinically, this means adagrasib increases exposure of cyp3a4 substrates, which may increase the risk of adverse reactions related to these substrates. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.
What To Tell Your Doctor or Pharmacist
If you are taking Sensitive Cyp3a Substrates and your doctor is considering prescribing Adagrasib (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider